IAVI and its partners are advancing a diverse porfolio of select preventive HIV vaccine candidates.
IAVI details its organizational strategic vision for the period 2011-2015 made.
Engage with IAVI on your social media networks.
Study Summary:
A clinical trial to evaluate the safety and immunogenicity of TBC-M4, an env, gag, tat-rev, and nef-RT MVA HIV vaccine and a prime-boost regimen with ADVAX, an env, gag, nef-tat and pol DNA HIV vaccine and TBC-M4.